Regenxbio CEO to step down after 15 years
BioPharma
Stay updated with breaking news from Rocket Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rocket Pharma has a pipeline of six gene therapy programs addressing cardiovascular and hematology-based diseases at the genetic level.
The gene therapy programs of Lexeo Therapeutics span rare forms of cardiomyopathy and certain types of Alzheimer’s disease. But Lexeo’s IPO comes as a rival gene therapy developer sues the biotech, claiming its work employs stolen trade secrets.
Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
/PRNewswire/ -- Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced today three new appointments to...